Imaging3 Inc., a development stage company introducing disruptive technologies in the medical imaging industry, has appointed Jeffrey N. Peterson to its board of directors effective immediately.
 
“Following Imaging3’s recent successful completion of critical activities facilitating a fresh start on its product development and approval goals for the introduction of an innovative breakthrough in cost-effective medical imaging, we are now focused on building the leadership team with the experience to bring this vision to fruition. I am delighted to lead this effort with the addition of Mr. Peterson to our board of directors. Having spent his early career rising through leadership roles at General Electric and Abbott Laboratories, as well as many years developing earlier stage private and public life sciences companies, Jeff brings deep experience in strategic leadership and connecting critical resources to assist us through our current stage and accelerate us towards achievement of our overall goals,” said CEO John Hollister.
 
Peterson brings broad executive general management and public, private and non-profit board leadership experience to Imaging3’s board. Peterson is currently serving as the chairman of Pressure BioSciences, a life sciences tools company focused on utilizing extreme pressure technologies for unique control over biomolecular interactions, analytical sample preparation, and nano-emulsion preparations. In addition, Peterson is the chairman and CEO of Veritomyx Inc., a Target Discovery Inc. subsidiary providing high-performance cloud computing SaaS solutions for advanced signal processing in mass spectrometry. Target Discovery is a personalized medicine diagnostics company focused on proteomic and isoformic biomarkers, where he has served as co-founder and CEO since 1999. 
 
Prior to his current roles, Peterson served as CEO of Sharpe, Peterson, Ocheltree & Associates, an international business development consulting firm assisting Fortune 500 and many smaller firms in business expansion and strategy. Peterson spent nine years in management roles for Abbott Laboratories, concluding as the CEO and general manager of Abbott South Africa. Prior to Abbott, Peterson spent 11 years rising through management roles for General Electric’s Engineered Materials and Plastics Groups. Peterson completed the entrepreneurship curriculum and holds bachelor of science and master's of science degrees in ChemE from MIT. He currently serves on the advisory board of the California Technology Council, served for 12 years on the Board of BayBio and is chair emeritus of the BayBio Institute. Peterson has also served as an active member of the Coalition for the 21st Century Medicine, and in BIO’s Personalized Medicine & Diagnostic Group.
 
“Imaging3 has impressed me with its remarkable story of resurgent promise and value," Peterson said. "Its transition management team deserves accolades for completing a phoenix-like transition from a daunting set of financial and legal challenges. The company has experienced fresh leadership under its new CEO John Hollister and has been repositioned for an unencumbered re-start on achievement of its exciting vision for a new global paradigm in cost-effective imaging, from industrial and food applications, to a full gamut of 2D, 3D and live surgical-guidance medical imaging. I have had the privilege of serving the medical and healthcare industries in both first and third world environments, and am excited and honored to have the opportunity to contribute to the realization of Imaging3’s goals and market potential.”
 
Imaging3 Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan that produces 3D X-ray images, effectively in real time. The SmartScan technology has the potential to allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. Imaging3’s technology exposes patients to significantly less harmful radiation than current equivalent imaging technologies such as CT scans. The company believes this will allow scans to be used in many settings where scanning is currently limited by concerns about radiation exposure. The technology also notably allows for reasonably convenient portability, easier installation and use-readiness, and a significantly reduced cost burden suitable for novel settings and for healthcare systems across varied global settings. Imaging3 plans to submit a 510K application to the U.S. Food and Drug Administration during 2018 in order to gain marketing authorization for initial applications for the SmartScan technology.